Given the preclinical evidence, whether SETD2 dysfunction was a complementary or independent factor to MSH-H and TMB to predict the prognostic of ICIs treatment needed to be figure out and whether this kind of dysfunction acted differently in different cancer types warrants further study. The gene discussed is SETD2; the disease is cancer.